Your browser doesn't support javascript.
loading
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor ß signaling.
Weissmueller, Susann; Manchado, Eusebio; Saborowski, Michael; Morris, John P; Wagenblast, Elvin; Davis, Carrie A; Moon, Sung-Hwan; Pfister, Neil T; Tschaharganeh, Darjus F; Kitzing, Thomas; Aust, Daniela; Markert, Elke K; Wu, Jianmin; Grimmond, Sean M; Pilarsky, Christian; Prives, Carol; Biankin, Andrew V; Lowe, Scott W.
Afiliación
  • Weissmueller S; Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Manchado E; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Saborowski M; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Morris JP; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Wagenblast E; Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
  • Davis CA; Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
  • Moon SH; Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
  • Pfister NT; Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
  • Tschaharganeh DF; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Kitzing T; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Aust D; Department of Visceral, Thoracic and Vascular Surgery, Technical University of Dresden, 01062 Dresden, Germany.
  • Markert EK; The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ 08540, USA.
  • Wu J; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, Sydney NSW 2010, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW 2010, Australia.
  • Grimmond SM; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Santa Lucia 4072, Australia; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Scotland G61 1BD, UK.
  • Pilarsky C; Department of Visceral, Thoracic and Vascular Surgery, Technical University of Dresden, 01062 Dresden, Germany.
  • Prives C; Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
  • Biankin AV; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, Sydney NSW 2010, Australia; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Scotland G61 1BD, UK.
  • Lowe SW; Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA; Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, New York, NY 10065, USA. Electronic address: lowes@mskc
Cell ; 157(2): 382-394, 2014 Apr 10.
Article en En | MEDLINE | ID: mdl-24725405
ABSTRACT
Missense mutations in the p53 tumor suppressor inactivate its antiproliferative properties but can also promote metastasis through a gain-of-function activity. We show that sustained expression of mutant p53 is required to maintain the prometastatic phenotype of a murine model of pancreatic cancer, a highly metastatic disease that frequently displays p53 mutations. Transcriptional profiling and functional screening identified the platelet-derived growth factor receptor b (PDGFRb) as both necessary and sufficient to mediate these effects. Mutant p53 induced PDGFRb through a cell-autonomous mechanism involving inhibition of a p73/NF-Y complex that represses PDGFRb expression in p53-deficient, noninvasive cells. Blocking PDGFRb signaling by RNA interference or by small molecule inhibitors prevented pancreatic cancer cell invasion in vitro and metastasis formation in vivo. Finally, high PDGFRb expression correlates with poor disease-free survival in pancreatic, colon, and ovarian cancer patients, implicating PDGFRb as a prognostic marker and possible target for attenuating metastasis in p53 mutant tumors.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Proteína p53 Supresora de Tumor / Receptor beta de Factor de Crecimiento Derivado de Plaquetas / Carcinoma Ductal Pancreático / Metástasis de la Neoplasia Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cell Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Proteína p53 Supresora de Tumor / Receptor beta de Factor de Crecimiento Derivado de Plaquetas / Carcinoma Ductal Pancreático / Metástasis de la Neoplasia Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cell Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos